Crossmark

Identification of telmisartan’s potential as NADH competitive lactate dehydrogenase A inhibitor unlocks its possibility for drug repurposing in cancer therapy

Crossref DOI link: https://doi.org/10.1007/s44371-025-00441-3

Published Online: 2025-12-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Paul, Sanjay Kumar

Guendouzi, Abdelmadjid

Dey, Sutithi

Guendouzi, Abdelkrim

Haldar, Rajen
Funding

Funding for this research was provided by:

Indian Council of Medical Research (F. No: 5/10/FR/94/2020-RBMCH, dated 28/12/2021)
License Information

Text and Data Mining valid from 2025-12-27

Version of Record valid from 2025-12-27
More Information

Article History

Received: 20 July 2025

Accepted: 16 December 2025

First Online: 27 December 2025

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below